Barclays PLC Invests $492,000 in Protara Therapeutics, Inc. (NASDAQ:TARA)

Barclays PLC purchased a new stake in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 93,239 shares of the company's stock, valued at approximately $492,000. Barclays PLC owned about 0.45% of Protara Therapeutics at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Bailard Inc. acquired a new position in Protara Therapeutics in the fourth quarter valued at $157,000. Commonwealth Equity Services LLC increased its position in Protara Therapeutics by 90.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after acquiring an additional 17,572 shares during the period. Geode Capital Management LLC increased its position in Protara Therapeutics by 21.0% in the 3rd quarter. Geode Capital Management LLC now owns 170,040 shares of the company's stock valued at $311,000 after acquiring an additional 29,514 shares during the period. ADAR1 Capital Management LLC purchased a new stake in Protara Therapeutics during the 4th quarter valued at approximately $648,000. Finally, Oppenheimer & Co. Inc. lifted its position in Protara Therapeutics by 12.4% during the 4th quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company's stock worth $1,064,000 after acquiring an additional 22,301 shares during the period. Institutional investors and hedge funds own 38.13% of the company's stock.

Insiders Place Their Bets

In other news, insider Jacqueline Zummo sold 21,224 shares of Protara Therapeutics stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total transaction of $96,144.72. Following the completion of the sale, the insider now directly owns 98,861 shares in the company, valued at approximately $447,840.33. This trade represents a 17.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on TARA shares. Lifesci Capital began coverage on Protara Therapeutics in a report on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 target price on the stock. Scotiabank assumed coverage on shares of Protara Therapeutics in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $12.00 price objective on the stock. HC Wainwright restated a "buy" rating and issued a $23.00 target price on shares of Protara Therapeutics in a research note on Monday, April 28th. Finally, Cantor Fitzgerald started coverage on shares of Protara Therapeutics in a report on Friday, March 14th. They issued an "overweight" rating on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $20.40.

Protara Therapeutics Stock Down 2.5%

TARA stock traded down $0.08 on Wednesday, reaching $3.14. 86,267 shares of the company's stock were exchanged, compared to its average volume of 343,400. The stock has a fifty day moving average of $3.98 and a 200-day moving average of $4.12. The firm has a market cap of $121.15 million, a PE ratio of -1.11 and a beta of 1.73. Protara Therapeutics, Inc. has a twelve month low of $1.60 and a twelve month high of $10.48.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.18. On average, equities research analysts predict that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.